Santhera Pharmaceuticals
Industry
- Pharmaceuticals
- Specialty Pharmaceuticals
- Vaccines
- Biotechnology
Other Names/Subsidiaries
- Oy Juvantia Pharma Ltd
Latest on Santhera Pharmaceuticals
Santhera Pharmaceuticals says that its Duchenne muscular dystrophy (DMD) treatment Agamree has got off to a strong start and while pricing negotiations are unsurprisingly proving tricky, the Swiss fi
The US Food and Drug Administration’s full approval of Sarepta Therapeutics, Inc. ’s Elevidys (delandistrogene moxeparvovec-rokl) pastes another jewel in the company’s “most contentious approvals” cr
In a recent discussion forum on China's WeChat social media platform, a group of patients whose sons are suffering from Duchenne muscular dystrophy (DMD) had good news to share - neurologists at one o
In 2023, the European Commission approved 36 medicines containing a new active substance, the lowest number since 2019 when just 28 NAS-containing drugs gained an EU-wide marketing authorization. Amon